Day 2 Recap: AAD 2026

To stay informed with the latest conference insights, follow us on LinkedIn, Facebook, X, and Instagram, and subscribe to receive our eNewsletters.

AAD 2026 Late-Breaker: Lawrence Eichenfield, MD, on Phase 2 Success of Nemolizumab in Pediatric AD

Late-breaking phase 2 findings presented at AAD show nemolizumab achieved high EASI-90 rates and rapid itch relief in pediatric patients with atopic dermatitis.

Reactivating the Follicle: PP405 Moves Toward Late-Stage Trials for Alopecia

Pelage’s PP405 novel topical reawakens dormant follicle stem cells, showing signs of terminal regrowth and fueling late-stage alopecia research.

Late-Breaking Data: Roflumilast Cream 0.05% Demonstrates Efficacy and Favorable Tolerability in Infantile Atopic Dermatitis

At AAD 2026, Christopher Bunick, MD, PhD, and Patrick Burnett, MD, PhD, discuss late-breaking data of roflumilast cream's improvements in infants with AD.

Alumis’ Envudeucitinib Meets Co-Primary Endpoints in ONWARD1 and ONWARD2 Phase 3 Trials

Late-breaking data shared at AAD 2026 supports oral TYK2 envudeucitinib's efficacy and safety in moderate-to-severe plaque psoriasis.

Biogen Announces Positive Phase 2 Results for Litifilimab in Cutaneous Lupus Erythematosus at AAD 2026

This portion of the AMETHYST trial is the second successful phase 2 study of litifilimab, an investigational monoclonal antibody for CLE.

Late-Breaking Data: Zasocitinib Achieves Rapid Skin Clearance in Plaque Psoriasis

Phase 3 data presented at AAD 2026 show once-daily oral therapy clears skin as early as week 4, offering a fast-acting option for patients.

Sonelokimab Demonstrates High HiSCR100 Rates and Durable Responses in Hidradenitis Suppurativa

Christopher Bunick, MD, PhD, and Kristian Reich, MD, PhD, discuss the long-term efficacy of sonelokimab, with more than 60% of patients achieving HiSCR75 and approximately 30% reaching HiSCR100.

AAD Meeting Snapshot: Late-Breaking Data in Atopic Dermatitis

Missed the late-breaking sessions? Review our quick guide of all the need-to-know data from AAD 2026.

Breaking Down Zasocitinib Data at AAD 2026

Melinda Gooderham, MSc, MD, FRCPC, reviewed late-breaking zasocitinib data for psoriasis, noting that 70% of patients reached sPGA 0/1.